<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ketamine as an adjuvant to opioids for cancer pain - Bell, RF - 2017 | Cochrane Library</title> <meta content="Ketamine as an adjuvant to opioids for cancer pain - Bell, RF - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003351.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ketamine as an adjuvant to opioids for cancer pain - Bell, RF - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003351.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003351.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Ketamine as an adjuvant to opioids for cancer pain" name="citation_title"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="raeb@frisurf.no" name="citation_author_email"/> <meta content="Christopher Eccleston" name="citation_author"/> <meta content="Eija A Kalso" name="citation_author"/> <meta content="Helsinki University and Helsinki University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD003351.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003351.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003351.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003351.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics [adverse effects, *therapeutic use]; Analgesics, Opioid [*therapeutic use]; Cancer Pain [*drug therapy]; Chemotherapy, Adjuvant; Hallucinations [chemically induced]; Ketamine [adverse effects, *therapeutic use]; Morphine [adverse effects, *therapeutic use]; Palliative Care; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003351.pub3&amp;doi=10.1002/14651858.CD003351.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003351\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003351\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","pl","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003351.pub3",title:"Ketamine as an adjuvant to opioids for cancer pain",firstPublishedDate:"Jun 28, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003351.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003351.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003351.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003351.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003351.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003351.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003351.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003351.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003351.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003351.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8188 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003351.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/appendices#CD003351-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ketamine as an adjuvant to opioids for cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#CD003351-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#CD003351-cr-0003">Christopher Eccleston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information#CD003351-cr-0004">Eija A Kalso</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information/en#CD003351-sec-0159">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003351.pub3">https://doi.org/10.1002/14651858.CD003351.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003351-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003351-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003351-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003351-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003351-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003351-abs-0001" lang="en"> <section id="CD003351-sec-0001"> <h3 class="title" id="CD003351-sec-0001">Background</h3> <p>This is an update of a review first published in 2003 and updated in 2012.</p> <p>Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine is known to have psychomimetic (including hallucinogenic), urological, and hepatic adverse effects. </p> </section> <section id="CD003351-sec-0002"> <h3 class="title" id="CD003351-sec-0002">Objectives</h3> <p>To determine the effectiveness and adverse effects of ketamine as an adjuvant to opioids for refractory cancer pain in adults. </p> </section> <section id="CD003351-sec-0003"> <h3 class="title" id="CD003351-sec-0003">Search methods</h3> <p>For this update, we searched MEDLINE (OVID) to December 2016. We searched CENTRAL (CRSO), Embase (OVID) and two clinical trial registries to January 2017. </p> </section> <section id="CD003351-sec-0004"> <h3 class="title" id="CD003351-sec-0004">Selection criteria</h3> <p>The intervention considered by this review was the addition of ketamine, given by any route of administration, in any dose, to pre‐existing opioid treatment given by any route and in any dose, compared with placebo or active control. We included studies with a group size of at least 10 participants who completed the trial. </p> </section> <section id="CD003351-sec-0005"> <h3 class="title" id="CD003351-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the search results and performed 'Risk of bias' assessments. We aimed to extract data on patient‐reported pain intensity, total opioid consumption over the study period; use of rescue medication; adverse events; measures of patient satisfaction/preference; function; and distress. We also assessed participant withdrawal (dropout) from trial. We assessed the quality of the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation). </p> </section> <section id="CD003351-sec-0006"> <h3 class="title" id="CD003351-sec-0006">Main results</h3> <p>One new study (185 participants) was identified by the updated search and included in the review. We included a total of three studies in this update. </p> <p>Two small studies, both with cross‐over design, with 20 and 10 participants respectively, were eligible for inclusion in the original review. One study with 20 participants examined the addition of intrathecal ketamine to intrathecal morphine, compared with intrathecal morphine alone. The second study with 10 participants examined the addition of intravenous ketamine bolus in two different doses to ongoing morphine therapy, compared with placebo. Both of these studies reported reduction in pain intensity and reduction in morphine requirements when ketamine was added to opioid for refractory cancer pain. The new study identified by the updated search had a parallel group design and 185 participants. This placebo‐controlled study examined rapid titration of subcutaneous ketamine to high dose (500 mg) in participants who were using different opioids. There were no differences between groups for patient‐reported pain intensity. </p> <p>Pooling of the data from the three included trials was not appropriate because of clinical heterogeneity. </p> <p>The study examining intrathecal drug administration reported no adverse events related to ketamine. In the study using intravenous bolus administration, ketamine caused hallucinations in four of 10 participants. In the rapid dose escalation/high‐dose subcutaneous ketamine study, there was almost twice the incidence of adverse events in the ketamine group, compared to the placebo group, with the most common adverse events being needle site irritation and cognitive disturbance. Two serious adverse events (bradyarrhythmia and cardiac arrest) thought to be related to ketamine were also reported in this trial. </p> <p>For all three studies there was an unclear risk of bias overall. Using GRADE, we judged the quality of the evidence to be very low due to study limitations and imprecision due to the small number of participants in all comparisons. </p> </section> <section id="CD003351-sec-0007"> <h3 class="title" id="CD003351-sec-0007">Authors' conclusions</h3> <p>Current evidence is insufficient to assess the benefits and harms of ketamine as an adjuvant to opioids for the relief of refractory cancer pain. The evidence was of very low quality, meaning that it does not provide a reliable indication of the likely effect, and the likelihood that the effect will be substantially different is high. Rapid dose escalation of ketamine to high dose (500 mg) does not appear to have clinical benefit and may be associated with serious adverse events. More randomised controlled trials (RCTs) examining specific low‐dose ketamine clinical regimens in current use are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003351-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003351-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003351-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003351-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003351-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003351-abs-0005">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003351-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003351-abs-0003" lang="en"> <h3>Adding ketamine to opioid for opioid‐resistant cancer pain</h3> <p><b>Bottom line</b> </p> <p>The benefits and harms of adding low‐dose ketamine to strong pain‐killers such as morphine for the relief of cancer pain are not yet established. High‐dose ketamine does not appear to be effective and may be associated with serious side effects. </p> <p><b>Background</b> </p> <p>This review is an update of a review first published in 2003 and updated in 2012.</p> <p>Morphine‐like drugs (opioids) are frequently prescribed for moderate and severe cancer pain, but in some cases these drugs are not effective. Ketamine, an anaesthetic agent, is used in low doses in palliative care to improve analgesia when opioids alone are ineffective. </p> <p><b>Study characteristics</b> </p> <p>In December 2016 and January 2017, we searched for clinical trials on the addition of ketamine to morphine‐like drugs for cancer pain. </p> <p>We found one new study, together with the two studies included in the original review. The three studies were very different, using different doses of ketamine, different routes of administration and different durations of treatment and it was not possible to combine the results of these studies. </p> <p><b>Key results</b> </p> <p>The two smallest studies reported that the addition of ketamine to morphine reduced pain intensity and morphine requirements. The third study which used high doses of ketamine reported no clinical benefit of adding ketamine to different opioids. Increased doses of ketamine in some participants caused side effects such as hallucinations. The study which examined high doses of ketamine reported two serious adverse events, which may have been related to ketamine. Although two out of three studies reported reduction in pain, this could be due to chance in such small studies. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence using four levels: very low, low, moderate, or high. Very low‐quality evidence means that we are very uncertain about the results. High‐quality evidence means that we are very confident in the results. The evidence from the studies was of very low quality. There were problems with the design of some studies and there were not enough data to answer some parts of our review question. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003351-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003351-sec-0105"></div> <h3 class="title" id="CD003351-sec-0106">Implications for practice</h3> <section id="CD003351-sec-0106"> <section id="CD003351-sec-0107"> <h5 class="title">For people with refractory cancer pain treated with opioid</h5> <p>The evidence base for ketamine as an adjuvant to opioids for the treatment of cancer pain is insufficient to enable us to draw any conclusions. Rapid dose escalation of ketamine to high dose (500 mg) does not appear to have clinical benefit and may be associated with serious adverse events. </p> </section> <section id="CD003351-sec-0108"> <h5 class="title">For clinicians</h5> <p>The evidence base for ketamine as an adjuvant to opioids for the treatment of cancer pain is insufficient to enable us to draw any conclusions. Rapid dose escalation of ketamine to high dose (500 mg) does not appear to have clinical benefit and may be associated with serious adverse events. </p> </section> <section id="CD003351-sec-0109"> <h5 class="title">For policy makers</h5> <p>The evidence base for ketamine as an adjuvant to opioids for the treatment of cancer pain is insufficient to enable us to draw any conclusions. Rapid dose escalation of ketamine to high dose (500 mg) does not appear to have clinical benefit and may be associated with serious adverse events. </p> </section> <section id="CD003351-sec-0110"> <h5 class="title">For funders of the intervention</h5> <p>The majority of this patient group are commonly in‐patients, due to refractory symptoms. Ketamine administered to hospitalised patients is an inexpensive treatment. However, the evidence base for ketamine as an adjuvant to opioids for the treatment of cancer pain is insufficient to enable us to draw any conclusions. </p> </section> </section> <h3 class="title" id="CD003351-sec-0111">Implications for research</h3> <section id="CD003351-sec-0111"> <section id="CD003351-sec-0112"> <h5 class="title">General implications</h5> <p>The amount of clinical trial evidence in this review is limited. Studies investigating specific low‐dose ketamine treatment regimens commonly used for refractory cancer pain are needed. </p> </section> <section id="CD003351-sec-0113"> <h5 class="title">Design</h5> <p>Conducting scientifically sound trials in a population of terminally ill cancer patients is a considerable challenge, and this is perhaps reflected in the small number of published trials available for this review. It is difficult to recruit large numbers of patients from this population. Cross‐over designs, as used in the two of the three included studies, may be more appropriate than placebo‐controlled parallel group studies. Where there are large trials, planned subgroup analyses should be considered. </p> </section> <section id="CD003351-sec-0114"> <h5 class="title">Measurement (endpoints)</h5> <p>Outcomes should be clearly defined, and trial managers should also restrict study outcomes to those that are the most clinically useful, such as which route of administration, relevant dose, co‐analgesic effects with specific opioids, and the cost to the patient in terms of adverse events. </p> <p>Whether ketamine is more effective in combination with specific opioids is not known, and this is an area for further research. Rapid titration of ketamine to high dose (<a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>) had no clinical benefit and was associated with adverse events. Further studies examining this specific treatment regimen are not warranted. Trials with S‐ketamine as an adjuvant to opioids might be appropriate. </p> </section> <section id="CD003351-sec-0115"> <h5 class="title">Other</h5> <p>Opioid tolerance may also be an issue. It has been suggested that pharmacological tolerance to opioid can develop early (<a href="./references#CD003351-bbs2-0045" title="LaulinJP , MauretteP , CorcuffJB , RivatC , ChauvinM , SimonnetG . The role of ketamine in preventing fentanyl‐induced hyperalgesia and subsequent acute morphine tolerance. Anesthesia and Analgesia2002;94(5):1263‐9. ">Laulin 2002</a>), but it is not clear how often it is a clinical problem in cancer patients. It may be difficult in this patient population to distinguish between tolerance and disease progression, both of which require an increase in opioid dose. In patients who appear to have a problem tolerating opioids, ketamine in low dose may be a treatment option. This is a topic for future research. </p> <p>More information is needed on whether the route of administration of ketamine has an impact on its effectiveness as an analgesic. If ketamine is used spinally, issues of neurotoxicity should be considered (<a href="./references#CD003351-bbs2-0040" title="KarpinskiN , DunnJ , HansenL , MasliahE . Subpial vacuolar myelopathy after intrathecal ketamine: report of a case. Pain1997;73(1):103‐5. ">Karpinski 1997</a>). </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003351-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003351-sec-0022"></div> <p>This is an update of a previously published review in the Cochrane Database of Systematic Reviews (2003, Issue 1 (<a href="./references#CD003351-bbs2-0079" title="BellR , EcclestonC , KalsoE . Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD003351] ">Bell 2003</a>)), and updated in 2012 (<a href="./references#CD003351-bbs2-0080" title="BellRF , EcclestonC , KalsoEA . Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD003351.pub2] ">Bell 2012b</a>) on ketamine as an adjuvant to opioids for cancer pain. </p> <section id="CD003351-sec-0023"> <h3 class="title" id="CD003351-sec-0023">Description of the condition</h3> <p>Studies report that moderate to severe pain is common in patients with advanced cancer (<a href="./references#CD003351-bbs2-0015" title="AreM , McIntyreA , ReddyS . Global disparities in cancer pain management and palliative care. Journal of Surgical Oncology2017;115(5):637‐41. ">Are 2017</a>). Cancer pain that is refractory to standard treatment occurs in 10% to 20% of these patients (<a href="./references#CD003351-bbs2-0014" title="AfsharimaniB , KindlK , GoodP , HardyJ . Pharmacological options for the treatment of refractory cancer pain‐ what is the evidence?. Supportive Care in Cancer2015;23(5):1473‐81. ">Afsharimani 2015</a>). Cancer pain is often of mixed aetiology and may have nociceptive, neuropathic and inflammatory components. Neuropathic pain which results from tumour infiltration in nerve plexi and damage of nerve tissue can be especially difficult to treat (<a href="./references#CD003351-bbs2-0029" title="FallonMT . Neuropathic pain in cancer. British Journal of Anaesthesia2013;111(1):105‐11. ">Fallon 2013</a>). Opioids (for example, morphine, fentanyl, hydromorphone, oxycodone, codeine) are frequently prescribed for the relief of moderate and severe cancer pain. However, not all cancer pain is sufficiently relieved by opioids alone. </p> </section> <section id="CD003351-sec-0024"> <h3 class="title" id="CD003351-sec-0024">Description of the intervention</h3> <p>The usual indication for using ketamine as an adjuvant to opioid in cancer pain is for pain which is unresponsive to opioids and adjuvant analgesics, for example in the case of refractory neuropathic pain or opioid tolerance. Clinical reports indicate that, when added to opioids, low subanaesthetic doses of ketamine may give improved analgesia (<a href="./references#CD003351-bbs2-0065" title="SosnowskiM , LossignolD , FodderieL . Reversibility of opioid insensitive pain (abstract). World Congress on Pain. Seattle: IASP Publications, 1993:16. ">Sosnowski 1993</a>; <a href="./references#CD003351-bbs2-0030" title="FinePG . Low‐dose ketamine in the management of opioid nonresponsive terminal cancer pain. Journal of Pain and Symptom Management1999;17:296‐300. ">Fine 1999</a>; <a href="./references#CD003351-bbs2-0017" title="BellRF . Low‐dose subcutaneous ketamine infusion and morphine tolerance. Pain1999;83:101‐3. ">Bell 1999</a>). The practice of using ketamine as an adjuvant to opioids in the treatment of cancer pain that does not respond to opioids alone, or to opioids in combination with adjuvant analgesic drugs, is discussed in several pain and palliative care textbooks (<a href="./references#CD003351-bbs2-0066" title="StannardCF , BoothS . Churchill's Pocketbook of Pain. Second Edition. Edinburgh: Churchill Livingstone, 2005:384. ">Stannard 2005</a>; <a href="./references#CD003351-bbs2-0070" title="TwycrossR , WilcockA , TollerCS . Symptom Management in Advanced Cancer. Fourth. Oxford: Palliativedrugs.com Ltd, 2009. ">Twycross 2009</a>; <a href="./references#CD003351-bbs2-0023" title="ChernyN , FallonM , KaasaS , PortenoyRK , CurrowDC . Oxford Textbook of Palliative Medicine. 5th Edition. Oxford: Oxford University Press, 2015. ">Cherny 2015</a>). Ketamine is not licensed for this purpose and this is an update of the first systematic review undertaken to establish the evidence base for this practice. </p> <p>Ketamine hydrochloride has been used as a general anaesthetic agent for over 30 years, and is commonly given intravenously or intramuscularly for surgical anaesthesia (<a href="./references#CD003351-bbs2-0031" title="FisherK , CoderreTJ , HagenNA . Targeting the N‐Methyl‐D‐Aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. Journal of Pain and Symptom Management2000;20(5):358‐73. ">Fisher 2000</a>). Ketamine causes dissociative anaesthesia and also has analgesic effects (<a href="./references#CD003351-bbs2-0035" title="Grahame‐SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug herapy. 3rd Edition. Oxford: Oxford University Press, 2002. ">Grahame‐Smith 2002</a>); because it increases sympathetic nervous system activity, it is a useful anaesthetic for high‐risk patients who require a high degree of sympathetic activity to maintain cardiovascular function. However, the benefits are tempered by the high incidence of hallucinations and other transient psychomimetic sequelae when ketamine is used for anaesthesia in adults (<a href="./references#CD003351-bbs2-0020" title="British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 63. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2012 (March). ">BNF 2012</a>). More recently, urological toxicity and hepatic toxicity have been described as adverse effects of ketamine (<a href="./references#CD003351-bbs2-0019" title="BellRF . Ketamine for chronic noncancer pain: concerns regarding toxicity. Current Opinion in Supportive and Palliative Care2012;6(2):183‐7. ">Bell 2012a</a>). </p> <p>In the 1980s ketamine was discovered to have N‐methyl‐D‐aspartate (NMDA) receptor antagonist properties and acts by blocking excitatory glutamate receptors in the central nervous system. There is an association between nociceptive activity involving the NMDA receptor and hyperalgesia/allodynia, and reduced opioid sensitivity (<a href="./references#CD003351-bbs2-0025" title="DickensonAH . Neurophysiology of opioid poorly responsive pain. Cancer Surveys: Palliative Medicine: Problem Areas in Pain and Symptom Management1994;21:5‐16. ">Dickenson 1994</a>). The NMDA receptor plays a role in the development of opioid tolerance (<a href="./references#CD003351-bbs2-0069" title="TrujilloKA , AkilH . Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK‐801. Science1991;251(4989):85‐7. ">Trujillo 1991</a>; <a href="./references#CD003351-bbs2-0051" title="MaoJ , PriceDD , MayerDJ . Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain1995;62:259‐74. ">Mao 1995</a>; <a href="./references#CD003351-bbs2-0052" title="MayerDJ , MaoJ , PriceDD . The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. NIDA‐Research Monographs1995;147:269‐98. ">Mayer 1995</a>). Currently, there is much focus on ketamine for the treatment of major depression. A recent paper reports that ketamine metabolites exert antidepressant actions independent of NMDA receptor inhibition (<a href="./references#CD003351-bbs2-0078" title="ZanosP , MoaddelR , MorrisPJ , GeorgiouP , FischellJ , ElmerGI , et al. NMDAR inhibition‐independent antidepressant actions of ketamine metabolites. Nature2016;533(7604):481‐6. ">Zanos 2016</a>). </p> <p>Evidence from experimental animal models, human volunteer studies and small clinical trials indicates that subanaesthetic doses of ketamine alleviate various chronic and neuropathic pain syndromes (<a href="./references#CD003351-bbs2-0031" title="FisherK , CoderreTJ , HagenNA . Targeting the N‐Methyl‐D‐Aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. Journal of Pain and Symptom Management2000;20(5):358‐73. ">Fisher 2000</a>). Ketamine has anti‐inflammatory effects and may have an effect in inflammatory pain (<a href="./references#CD003351-bbs2-0024" title="DaleO , SomogyiAA , LiY , SullivanT , ShavitY . Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta‐analysis. Anesthesia and Analgesia2012;115:934‐43. ">Dale 2012</a>; <a href="./references#CD003351-bbs2-0063" title="SawynokJ . Topical and peripheral ketamine as an analgesic. Anesthesia and Analgesia2014;119(1):170‐8. ">Sawynok 2014</a>). However, the clinical use of ketamine at subanaesthetic dose levels has also been restricted by unpleasant adverse effects, typically sedation, nausea, disagreeable psychological disturbances or hallucinations (<a href="./references#CD003351-bbs2-0074" title="WillettsJ , BalsterRL , LeanderD . The behavioral pharmacology of NMDA receptor antagonists. Trends in Pharmacological Sciences1990;11:423‐8. ">Willetts 1990</a>). </p> <p>Racemic ketamine is a mixture of two stereoisomers: R(‐) and S(+). More recently, S‐ketamine has been introduced. S(+) ketamine produces longer hypnosis than the (‐) isomer, and causes a greater rise in blood pressure and heart rate, less locomotor activity, and a shorter recovery time, and it is postulated to have twice the analgesic efficacy of racemic ketamine. S(+) ketamine is also thought to have a safer adverse effect profile (<a href="./references#CD003351-bbs2-0035" title="Grahame‐SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug herapy. 3rd Edition. Oxford: Oxford University Press, 2002. ">Grahame‐Smith 2002</a>). The majority of published clinical studies in postoperative and chronic pain have used racemic ketamine. For a review on the pharmacokinetics of ketamine see <a href="./references#CD003351-bbs2-0061" title="PeltoniemiMA , HagelbergNM , OlkkolaKT , SaariTI . Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anaesthesia and pain therapy. Clinical Pharmacokinetics2016;55(9):1059‐77. ">Peltoniemi 2016</a>. The oral bioavailability of ketamine is low and the drug undergoes fast cytochrome P450 (CYP) mediated N‐demethylation to norketamine. Approximately 80% of ketamine undergoes N‐demethylation to norketamine by CYP3A and CYP2B6 enzymes (<a href="./references#CD003351-bbs2-0041" title="KharaschED , LabrooR . Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology1992;77(6):1201‐7. ">Kharasch 1992</a>; <a href="./references#CD003351-bbs2-0077" title="YanagiharaY , KariyaS , OhtaniM , UchinoK , AoyamaT , YamamuraY , et al. Involvement of CYP2B6 in n‐demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition2001;29(6):887‐90. ">Yanagihara 2001</a>; <a href="./references#CD003351-bbs2-0037" title="HijaziY , BoulieuR . Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N‐demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition2002;30(7):853‐8. ">Hijazi 2002</a>), with a smaller amount being metabolised to 4‐and 6‐hydroxyketamines (<a href="./references#CD003351-bbs2-0076" title="WoolfTF , AdamsJD . Biotransformation of ketamine, (Z)‐6‐hydroxyketamine, and (E)‐6‐hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica1987;17(7):839‐47. ">Woolf 1987</a>). Compared to ketamine, norketamine is an approximately three to five times weaker NMDA receptor antagonist (<a href="./references#CD003351-bbs2-0046" title="LeungLY , BaillieTA . Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)‐6‐hydroxynorketamine. Journal of Medicinal Chemistry1987;29(11):2396‐9. ">Leung 1986</a>; <a href="./references#CD003351-bbs2-0027" title="EbertB , MikkelsenS , ThorkildsenC , BorgbjergFM . Norketamine, the main metabolite of ketamine, is a non‐competitive NMDA receptor antagonist in the rat brain and spinal cord. European Journal of Pharmacology1997;333(1):91‐104. ">Ebert 1997</a>). Being metabolised by CYP3A enzymes, ketamine may have significant interactions with opioids and other drugs. Studies in rodents indicate important interactions between ketamine and opioids. <a href="./references#CD003351-bbs2-0028" title="EdwardsSR , MintoCF , MatherLE . Concurrent ketamine and alfentanil administration:pharmacokinetic considerations. British Journal of Anaesthesia2002;88(1):94‐100. ">Edwards 2002</a> reported that in mice, distribution of ketamine into the brain was increased by low plasma concentrations of alfentanil. Recently <a href="./references#CD003351-bbs2-0047" title="LiliusTO , JokinenV , NeuvonenMS , NiemiM , KalsoEA , RauhalaPV . Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. British Journal of Pharmacology2015;172(11):2799‐813. ">Lilius 2015</a> found that ketamine co‐administration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. </p> <p>Ketamine has multiple routes of administration and is commonly given as an adjuvant to pre‐existing opioid treatment. A number of systematic reviews report that ketamine is effective in acute postoperative pain and reduces morphine requirements (<a href="./references#CD003351-bbs2-0018" title="BellRF , DahlJB , MooreRA , KalsoE . Perioperative ketamine for acute postoperative pain. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004603.pub2] ">Bell 2006</a>; <a href="./references#CD003351-bbs2-0044" title="LaskowskiK , StirlingA , McKayWP , LimHJ . A systematic review of intravenous ketamine for postoperative analgesia. Canadian Journal of Anesthesia2011;58:911‐23. ">Laskowski 2011</a>; <a href="./references#CD003351-bbs2-0016" title="AssoulineB , TramèrMR , KreienbühlL , EliaN . Benefit and harm of adding ketamine to an opioid in a patient‐controlled analgesia device for the control of postoperative pain: systematic review and meta‐analyses of randomized controlled trials with trial sequential analyses. Pain2016;157(12):2854‐64. ">Assouline 2016</a>). </p> </section> <section id="CD003351-sec-0025"> <h3 class="title" id="CD003351-sec-0025">How the intervention might work</h3> <p>By blocking activity at the NMDA receptor, ketamine may reduce neuropathic‐related cancer pain. Blocking NMDA receptor activity may reduce opioid tolerance thus increasing/restoring the analgesic effect of opioid. Ketamine has anti‐inflammatory effects and may be beneficial in inflammatory cancer pain. </p> </section> <section id="CD003351-sec-0026"> <h3 class="title" id="CD003351-sec-0026">Why it is important to do this review</h3> <p>This is an update of a Cochrane review first published in 2003, and previously updated in 2012. Ketamine is routinely used in the palliative care setting for the treatment of refractory cancer pain. Earlier versions of this review found limited and heterogenous data, and there was insufficient evidence to be able to make any conclusions. In recent years the standards used to assess evidence in pain trials have changed substantially, for example there is now particular attention being paid to participant withdrawal from trials, and statistical imputation following withdrawal, which can substantially alter estimates of efficacy. The most important change is the move from using average pain scores, or average change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) (<a href="./references#CD003351-bbs2-0059" title="Pain , Palliative and Supportive Care Group. Authoring or assessing a Cochrane Protocol, Review, or Review Update for the PaPaS Review Group (AUREF). papas.cochrane.org/papas‐documents (accessed 6 April 2017). ">PaPaS 2012</a>). This update assesses the current evidence using the new criteria for what constitutes reliable evidence in pain trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003351-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003351-sec-0027"></div> <p>To determine the effectiveness and adverse effects of ketamine as an adjuvant to opioids for refractory cancer pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003351-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003351-sec-0028"></div> <section id="CD003351-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003351-sec-0030"> <h4 class="title">Types of studies</h4> <p> <ul id="CD003351-list-0001"> <li> <p>Randomised controlled trials (RCTs)</p> </li> <li> <p>Double‐blind studies</p> </li> <li> <p>Placebo‐ or active‐controlled trials, both with or without cross‐over, in in‐patient and out‐patient settings </p> </li> </ul> </p> <p>We excluded studies with a group size of fewer than 10 participants who completed the study. </p> </section> <section id="CD003351-sec-0031"> <h4 class="title">Types of participants</h4> <p>The population addressed by the review included adult patients (aged 18 or over) with cancer and pain despite being currently treated by an opioid agonist (e.g. morphine, fentanyl, oxycodone), in any dose and by any route. We excluded studies including patients who were on an established NMDA‐receptor antagonist treatment before the study began. We did not consider volunteer studies. </p> </section> <section id="CD003351-sec-0032"> <h4 class="title">Types of interventions</h4> <p>The intervention considered by this review was the addition of ketamine, given by any route of administration, in any dose, to pre‐existing opioid treatment given by any route and in any dose. </p> </section> <section id="CD003351-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD003351-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure was patient‐reported pain intensity (e.g. visual analogue scales (VAS) and verbal rating scales). </p> </section> <section id="CD003351-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome measures were:</p> <p> <ul id="CD003351-list-0002"> <li> <p>total opioid consumption over the study period;</p> </li> <li> <p>rescue medication;</p> </li> <li> <p>adverse events;</p> </li> <li> <p>measures of patient satisfaction/ preference;</p> </li> <li> <p>function;</p> </li> <li> <p>distress.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003351-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003351-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for this update:</p> <p> <ul id="CD003351-list-0003"> <li> <p>CENTRAL (CRSO) April 2012 to January 2017;</p> </li> <li> <p>MEDLINE (OVID) May 2012 to December 2016;</p> </li> <li> <p>Embase (OVID) May 2012 to 2017 week 1.</p> </li> </ul> </p> <p>Please see <a href="./appendices#CD003351-sec-0118">Appendix 1</a> and <a href="./appendices#CD003351-sec-0119">Appendix 2</a> for the searches conducted for the original review in 2003. For the searches conducted for the update in 2012 please see <a href="./appendices#CD003351-sec-0120">Appendix 3</a>, <a href="./appendices#CD003351-sec-0121">Appendix 4</a> and <a href="./appendices#CD003351-sec-0122">Appendix 5</a>. For searches conducted for the current update please see <a href="./appendices#CD003351-sec-0123">Appendix 6</a>. </p> </section> <section id="CD003351-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We also searched two clinical trial registers (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) to identify additional published or unpublished data. </p> <section id="CD003351-sec-0039"> <h5 class="title">Language</h5> <p>We did not restrict searches or inclusion by language.</p> </section> </section> </section> <section id="CD003351-sec-0040"> <h3 class="title" id="CD003351-sec-0040">Data collection and analysis</h3> <section id="CD003351-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RB and EK) independently assessed the titles and abstracts from each of the electronic databases searched for relevance. We retrieved potentially relevant trial reports in full and three review authors (RB, CE, EK) assessed them for inclusion in the review. </p> </section> <section id="CD003351-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We designed a data extraction form, and two review authors (RFB, EK) independently collected the following data items if available. </p> <p> <ul id="CD003351-list-0004"> <li> <p>Publication details.</p> </li> <li> <p>Patient population, number of participants, age, condition.</p> </li> <li> <p>Description of the intervention(s) and control.</p> </li> <li> <p>Outcomes: pain intensity, total opioid consumption, rescue medication, measures of patient satisfaction/preference, distress and function. </p> </li> <li> <p>Adverse events (major and minor).</p> </li> <li> <p>Quality (evaluated using the Oxford Quality Scale (<a href="./references#CD003351-bbs2-0038" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17:1‐12. ">Jadad 1996</a>)). </p> </li> <li> <p>Validity (evaluated using the Oxford Pain Validity Scale (OPVS) (<a href="./references#CD003351-bbs2-0064" title="SmithLA , OldmanAD , McQuayHJ , MooreRA . Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain2000;86:119‐32. ">Smith 2000</a>)). </p> </li> </ul> </p> <p>This information is recorded in the '<a href="./references#CD003351-sec-0166" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD003351-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RFB, EK) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003351-bbs2-0036" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion with a third author (CE). We completed 'Risk of bias' table for each included study using the 'Risk of bias' tool in RevMan (<a href="./references#CD003351-bbs2-0062" title="The Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager. Version 5.3.. Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We assessed the following for each included study.</p> <p> <ul id="CD003351-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, such as identical tablets matched in appearance and smell, or a double‐dummy technique); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study has a clear statement that outcome assessors were unaware of treatment allocation, and ideally describes how this was achieved); unclear risk of bias (study states that outcome assessors were blind to treatment allocation but lacks a clear statement on how it was achieved). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants did not complete the study or used ‘baseline observation carried forward’ analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Selective reporting (reporting bias). We assessed the risk of reporting bias as: low risk of bias (all intended outcomes reported); unclear risk of bias (any anomaly in reporting, such as participants contributing more than one set of data, or some outcomes not participant‐reported); high risk of bias (prespecified outcome of interest not reported). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD003351-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes we planned to calculate the risk ratio (RR) and the corresponding 95% confidence interval (CI) and P value. We planned to calculate the number needed to treat for an additional beneficial outcome (NNTB)/number needed to treat for an additional harmful outcome (NNTH) as the reciprocal of the absolute risk difference (<a href="./references#CD003351-bbs2-0053" title="McQuayH , MooreR . An Evidence‐Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. ">McQuay 1998</a>). For continuous outcomes, we planned to calculate the mean difference (MD) and its corresponding 95% CI when means and standard deviations (SD) were available. If such information was unavailable we planned to use the methods described in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to calculate standardised mean differences (SMD), from for example, F ratios, t values, Chi<sup>2</sup> values and correlation coefficients (<a href="./references#CD003351-bbs2-0036" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Higgins 2011</a>). In cases where continuous measures were used to assess the same outcomes using different scales, we would have pooled these data using Hedges' g to estimate the SMD. When effect sizes could not be pooled, we planned to report study level effects narratively. </p> </section> <section id="CD003351-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We only included studies that randomised the individual participant.</p> </section> <section id="CD003351-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We assessed missing data in the included studies. Where possible, we investigated and reported the reasons and numbers of those dropping out of each included study. For dichotomous outcomes, we planned to perform an intention‐to‐treat (ITT) analysis. If there was missing participant information, we recorded this and commented in the individual study's 'Risk of bias' table. Participants with missing data would be assigned to a 'zero improvement category'. </p> <p>We paid particular attention to methods used for imputation of missing data due to withdrawals for adverse events and lack of efficacy. Where data were missing for substantial numbers of participants (greater than 10%), we would have rated the study as high risk of bias. </p> </section> <section id="CD003351-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to deal with clinical heterogeneity by combining studies that examined similar conditions. Statistical heterogeneity would have been assessed visually (<a href="./references#CD003351-bbs2-0043" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. ">L'Abbé 1987</a>). </p> </section> <section id="CD003351-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We looked for the original trial protocols of the included studies and compared the results to these when they were found. When no protocol was available, we compared the reported outcomes against the Methods section of the paper to look for selective reporting of outcomes. </p> <p>We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result for pain clinically irrelevant (usually taken to mean an NNTB of 10 or higher) (<a href="./references#CD003351-bbs2-0056" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. ">Moore 2008</a>). In the event, there were insufficient data for statistical analysis. </p> </section> <section id="CD003351-sec-0049"> <h4 class="title">Data synthesis</h4> <section id="CD003351-sec-0050"> <h5 class="title">Quality of the evidence</h5> <p>We planned to combine data in a series of meta‐analyses on both primary and secondary outcomes. </p> <p>We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system to rank the quality of the evidence using the GRADE profiler Guideline Development Tool software (<a href="./references#CD003351-bbs2-0034" title="BrozekJ , OxmanA , SchünemannH . GRADEpro Guideline Development Tool [Software].. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org., 2015. ">GRADEpro GDT 2015</a>), and the guidelines provided in Chapter 12.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003351-bbs2-0036" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> <p>The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence: </p> <p> <ul id="CD003351-list-0006"> <li> <p>high: we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p>very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We decreased the grade rating by one (‐ 1) or two (‐ 2) if we identified:</p> <p> <ul id="CD003351-list-0007"> <li> <p>serious (‐ 1) or very serious (‐ 2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐ 1);</p> </li> <li> <p>some (‐ 1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>serious (‐1) or very serious (‐2) imprecise or sparse data;</p> </li> <li> <p>high probability of reporting bias (‐ 1).</p> </li> </ul> </p> </section> <section id="CD003351-sec-0051"> <h5 class="title">'Summary of findings' table</h5> <p>We planned to include a 'Summary of findings' table as set out in the PaPaS author guide <a href="./references#CD003351-bbs2-0059" title="Pain , Palliative and Supportive Care Group. Authoring or assessing a Cochrane Protocol, Review, or Review Update for the PaPaS Review Group (AUREF). papas.cochrane.org/papas‐documents (accessed 6 April 2017). ">PaPaS 2012</a> and recommended in the Cochrane Handbook (Chapter 11, <a href="./references#CD003351-bbs2-0036" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Higgins 2011</a>) to present the main findings in a transparent and simple tabular format. However, we judged that a 'Summary of findings' table with only three very different studies would be unhelpful. </p> </section> </section> <section id="CD003351-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan subgroup analyses.</p> </section> <section id="CD003351-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Had there been sufficient data available, we would have examined the robustness of meta‐analyses by conducting a sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003351-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003351-sec-0054"></div> <section id="CD003351-sec-0055"> <h3 class="title">Description of studies</h3> <p>The original review included one study which compared intrathecal ketamine + intrathecal morphine with intrathecal morphine alone (<a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>), and one study which compared intravenous ketamine bolus with intravenous bolus of placebo as a supplement to ongoing morphine therapy (<a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>). We found one new study for this update which compared subcutaneous infusion of ketamine at three dose levels (100 mg, 300 mg, or 500 mg) with placebo in participants with ongoing treatment with opioids (<a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>). </p> <section id="CD003351-sec-0056"> <h4 class="title">Results of the search</h4> <p>The updated searches of the three databases (see <a href="#CD003351-sec-0037">Electronic searches</a>) retrieved 271 records. Our searches of the trials registers did not identify further studies. Our screening of the reference lists of the included publications did not reveal additional RCTs. We therefore had a total of 271 records. </p> <p>Once duplicates had been removed, we had a total of 216 records. We excluded 215 records based on titles and abstracts. We obtained the full text of the remaining record and this study was included (<a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>). For a further description of our screening process, see the study flow diagram (<a href="#CD003351-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003351-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003351-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified three ongoing studies and added these records to Characteristics of studies awaiting classification. Two additional trials with status 'completed' do not appear to have been published and possibly represent double registration of the same trial. These are described under <a href="./references#CD003351-sec-0168" title="">Characteristics of ongoing studies</a><i>.</i> </p> <p>Protocols for the studies by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> were not available. The protocol for the study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> was retrieved. </p> </section> <section id="CD003351-sec-0057"> <h4 class="title">Included studies</h4> <section id="CD003351-sec-0058"> <h5 class="title">Study design</h5> <p>Two included studies (<a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>; <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>) had a cross‐over design. The trial conducted in Taiwan by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> compared ketamine and morphine with morphine alone. The time period over which the intervention was assessed was not stated in the trial report, but there is an implication that the study was conducted over a period of days. (Attempts to contact the author to confirm the trial duration were not successful). The trial conducted in Italy by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> was a placebo‐controlled trial and was conducted over a three‐hour period. The most recent trial <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> was a multisite, dose‐escalation, double‐blind, randomised, placebo‐controlled parallel group study with a duration of five days. </p> </section> <section id="CD003351-sec-0059"> <h5 class="title">Study population</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>: Twenty hospitalised participants (10 men and 10 women) aged 22 to 69 years with cancer pain of variable severity treated with opioids. The primary cancer sites were stomach, cervix, liver, lung, colon, pancreas. </p> <p><a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>: Ten participants (seven men and three women) aged 21 to 69 years who had pain unrelieved by their dose of morphine, and a Karnofsky status of 50 or more. The primary cancer sites were: bladder, rectum, lung, histiocytoma and uterus. In this study, the pain was classified as being "neuropathic" or having a "neuropathic component". </p> <p><a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>: Hospitalised palliative care participants aged 18 or older, with refractory chronic nociceptive or neuropathic pain secondary to cancer or its treatment (Brief Pain Inventory (BPI) average pain score ≥ 3 despite ongoing treatment with opioids and co‐analgesics at predefined dose levels). One hundred and eighty participants were randomly assigned, two were deleted from the analysis, 93 were allocated to ketamine and 92 to placebo. Ninety‐one received ketamine and 90 received placebo. One hundred and forty‐nine were defined as having completed the trial, although only 39 participants in the ketamine arm and 35 participants in the placebo arm received either ketamine or placebo for the full five‐day period. </p> </section> <section id="CD003351-sec-0060"> <h5 class="title">Intervention</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> assessed intrathecal ketamine 1.0 mg twice daily as adjuvant to intrathecal morphine, compared with intrathecal morphine alone. The morphine dose was titrated until participants' pain relief had been stable for 48 hours, then the participants were randomly crossed over (no washout period) to morphine plus ketamine or continued on morphine (control), administered intrathecally twice a day. </p> <p><a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> assessed two doses of ketamine (0.25 mg/kg and 0.5 mg/kg) administered intravenously as a bolus as adjuvant to ongoing morphine therapy, compared with saline. Patients were randomly assigned to receive in turn either 0.25 mg/kg or 0.5 mg/kg ketamine or saline, with a two‐day washout period between each intervention/control. </p> <p><a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> assessed either placebo (normal saline) or ketamine at three dose levels (100 mg, 300 mg, or 500 mg) as a subcutaneous infusion in a five‐day schedule, starting at the first dose level (100 mg/24 hours), as a supplement to ongoing opioid therapy. If 80% of the study drug had been delivered, and average pain improved by ≥ 2 BPI units, with no more than four doses of breakthrough medication, the dose remained the same. If not, the dose was increased to the next level. </p> <p>Morphine was the only opioid participants received in the studies by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>. The route of administration of morphine in the study by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> was intrathecal, while morphine was given by varied routes of administration (oral, intravenous or subcutaneous) in the trial by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>. The opioid was not standardised in the study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> where participants used different opioids (morphine, oxycodone, hydromorphone, methadone, fentanyl, sufentanil, alfentanil) given by different routes of administration (oral, transdermal or parenteral). </p> <p>It is assumed that racemic ketamine was used in all three studies.</p> </section> <section id="CD003351-sec-0061"> <h5 class="title">Rescue medication</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>: In this trial a rescue dose of 5 mg morphine was administered intramuscularly as needed. <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> does not report the use of rescue medication. <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> states that the participants had access to breakthrough analgesia and record the number of doses, but do not describe the rescue medication. </p> </section> <section id="CD003351-sec-0062"> <h5 class="title">Outcomes</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> measured patient‐reported pain intensity (zero to 10 numerical, 10 worst pain imaginable); pain frequency (four‐point verbal ordinal scale), group morphine dose, total titrated intrathecal morphine, total rescue medication, frequency of intrathecal titration. <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> measured patient‐reported pain intensity (zero to 10 numerical scale) at 30‐, 60‐, 90‐, 120‐, and 180‐minute intervals; and adverse events. <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> defined the primary outcome as a positive response defined as a "clinically relevant improvement in pain" at the end of the ive‐day study period. A "clinically relevant improvement in pain" was defined as a reduction in BPI average pain score by ≥ 2 points from baseline in the absence of more than four breakthrough doses of analgesia over the previous 24 hours. Secondary outcomes included pain assessments at days two to five and adverse events. </p> <p>See <a href="./references#CD003351-sec-0166" title="">Characteristics of included studies</a> tables. </p> </section> </section> <section id="CD003351-sec-0063"> <h4 class="title">Excluded studies</h4> <p>For this update we identified one eligible study (<a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>), which was included. Overall, we excluded five studies. (For studies previously excluded see <a href="./references#CD003351-sec-0167" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD003351-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003351-fig-0002">Figure 2</a>; <a href="#CD003351-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003351-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003351-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003351-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003351-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003351-sec-0065"> <h4 class="title">Allocation</h4> <p>The studies by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> stated that patients were randomised to treatment and control groups, but in neither trial was the process of randomisation described (unclear risk of bias). In the trial by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> each site pharmacy used randomisation tables from an independent central registry. Stratification was by pain type (neuropathic or nociceptive) and randomisation was double‐blinded, allocated by blocks of four in a 1:1 ratio for each strata by site. We judged this study to be at low risk of bias. </p> </section> <section id="CD003351-sec-0066"> <h4 class="title">Blinding</h4> <section id="CD003351-sec-0067"> <h5 class="title">Performance bias</h5> <p>Participants, investigators and nurses were blinded using a double‐dummy technique in <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and the drugs were prepared in identical syringes by a person not involved in the study and administered in the same volume in <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>. The <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> trial is described as double‐blinded. The blinding procedure was not described in the final paper, but was described in the study protocol ("All syringes will look identical in volume and colour"). </p> <p>There were no specific procedures to check for performance bias in any of the three included trials. In <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>, one participant in the morphine phase and no participants in the combined morphine and ketamine phase reported psychotoxicity (hallucinations), whereas in <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> ketamine caused hallucinations in four of 10 participants, so the participants may have been able to tell which drug they had received. The study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> involved rapid dose escalation of ketamine to high doses and blinding could have been compromised due to adverse effects from ketamine. We judged the study by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> at low risk of performance bias and the studies by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> and <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> at unclear risk of performance bias. </p> </section> <section id="CD003351-sec-0068"> <h5 class="title">Detection bias</h5> <p>We judged the study by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> at low risk of detection bias and the studies by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> and <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> at unclear risk of detection bias. </p> </section> </section> <section id="CD003351-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>All participants were accounted for in the trials by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>. <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> reported an ITT analysis, but imputed missing data using last observation carried forward (LOCF). We judged this study at unclear risk of bias. </p> </section> <section id="CD003351-sec-0070"> <h4 class="title">Selective reporting</h4> <p>There were no problems of selective reporting detected in the trials by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> and <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>. In the trial by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>, assessing "the effect of ketamine on total opioid dose" was mentioned in the protocol as a "secondary objective", but was not reported. We judged this study at unclear risk of bias. </p> </section> <section id="CD003351-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <section id="CD003351-sec-0072"> <h5 class="title">Size</h5> <p>The cross‐over studies by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> had respectively 20 and 10 participants (fewer than 50 participants per treatment arm). We judged these trials at high risk of bias. The parallel group trial by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> had 185 participants (between 50 and 199 participants per treatment arm) and we judged it at unclear risk of bias. </p> </section> <section id="CD003351-sec-0073"> <h5 class="title">Oxford quality assessment</h5> <p>Quality scores derived using the Oxford quality scale (<a href="./references#CD003351-bbs2-0038" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17:1‐12. ">Jadad 1996</a>) were three for both <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> and <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>, and four for <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> out of a possible maximum of five points. </p> <p>Using the method derived by <a href="./references#CD003351-bbs2-0064" title="SmithLA , OldmanAD , McQuayHJ , MooreRA . Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain2000;86:119‐32. ">Smith 2000</a>, the three included studies (<a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>; <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>; <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>) scored 13, 12 and 12, respectively on the Oxford Pain Validity Scale, a zero to 16‐point validity scale. </p> </section> </section> </section> <section id="CD003351-sec-0074"> <h3 class="title" id="CD003351-sec-0074">Effects of interventions</h3> <p>It was not possible to perform a quantitative meta‐analysis because of the small number of participants in two of the trials, lack of extractable data and general heterogeneity of the data. A description of the results from the three included trials is given below. None of the trials provided data on pain relief, patient satisfaction/preference, function or distress. For all outcomes we judged the quality of the evidence to be very low. We downgraded one level for serious risk of bias and two levels for very serious imprecision due to very small number of participants in two of the comparisons and small number of participants in the third comparison. </p> <section id="CD003351-sec-0075"> <h4 class="title">Patient‐reported pain intensity</h4> <section id="CD003351-sec-0076"> <h5 class="title">Ketamine 1.0 mg twice daily (intrathecal)</h5> <p>One study (<a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>) assessed adjuvant ketamine 1.0 mg administered intrathecally. The trial duration is not specified, but it was conducted over several days. Pain intensity on a numerical rating scale zero to 10 was reduced from 7.95 ± 0.25 to 2.45 ± 0.17 after adjuvant treatment with ketamine. </p> </section> <section id="CD003351-sec-0077"> <h5 class="title">Ketamine 0.25 mg/kg (intravenous)</h5> <p>One trial (<a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>) assessed pain intensity over three hours. Mean pain intensity scores showed a reduction in pain intensity after 30 minutes compared with saline solution; after 60 minutes the analgesic effect of ketamine began to diminish but continued to have an effect for a period of three hours. </p> </section> <section id="CD003351-sec-0078"> <h5 class="title">Ketamine 0.5 mg/kg (intravenous)</h5> <p>One trial (<a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>) assessed pain intensity over three hours. Mean pain intensity scores showed a significant reduction after 30 minutes compared with saline solution. The analgesic effect of ketamine continued throughout the three‐hour period. </p> </section> <section id="CD003351-sec-0079"> <h5 class="title">Ketamine dose escalation 100 mg, 300 mg, 500 mg (subcutaneous)</h5> <p>One study (<a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>) assessed average BPI pain score on day six, following dose escalation of ketamine subcutaneous infusion in a five‐day schedule, starting at the first dose level (100 mg/24 hours). If 80% of the study drug had been delivered, and average pain improved by ≥ 2 BPI units, with no more than four breakthrough doses, the dose remained the same. If not, the dose was increased to the next level. There was no significant difference in patient‐reported pain intensity between the placebo and ketamine arms. </p> </section> </section> <section id="CD003351-sec-0080"> <h4 class="title">Total opioid consumption</h4> <section id="CD003351-sec-0081"> <h5 class="title">Ketamine 1.0 mg twice daily (intrathecal)</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> reported that on the last day of the morphine phase, participants required intrathecal morphine 0.38 mg/day ± 0.04 mg/day. On the last day of the combined ketamine and morphine (K+M) phase, intrathecal morphine requirements had decreased to 0.17 mg/day ± 0.02 mg/day. The total titrated dose of intrathecal morphine, total dose of intramuscular rescue morphine during the K+M phase was less than in the morphine phase. </p> </section> <section id="CD003351-sec-0082"> <h5 class="title">Ketamine 0.25 mg/kg and 0.5 mg/ kg (intravenous)</h5> <p><a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> did not provide information on this outcome. </p> </section> <section id="CD003351-sec-0083"> <h5 class="title">Ketamine dose escalation 100 mg, 300 mg, 500 mg (subcutaneous)</h5> <p><a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> did not provide information on this outcome. </p> </section> </section> <section id="CD003351-sec-0084"> <h4 class="title">Rescue medication</h4> <section id="CD003351-sec-0085"> <h5 class="title">Ketamine 1.0 mg twice daily (intrathecal)</h5> <p><a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> reported that the total dose of rescue morphine during the K+M phase was less than the morphine phase. </p> </section> <section id="CD003351-sec-0086"> <h5 class="title">Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)</h5> <p><a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> did not report the use of rescue medication, but stated in the text that the administration of ketamine allowed for "a reduction of opioid doses". </p> </section> <section id="CD003351-sec-0087"> <h5 class="title">Ketamine dose escalation 100 mg, 300 mg, 500 mg (subcutaneous)</h5> <p><a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> reported that there was no significant group difference in the median number of breakthrough analgesic doses given during the study. </p> </section> </section> <section id="CD003351-sec-0088"> <h4 class="title">Adverse events</h4> <section id="CD003351-sec-0089"> <h5 class="title">Psychomimetic adverse events</h5> <section id="CD003351-sec-0090"> <h6 class="title">Ketamine 1.0 mg twice daily (intrathecal)</h6> <p>One participant in the morphine only arm of the <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> study reported hallucinations. There were none reported in the ketamine arm. </p> </section> <section id="CD003351-sec-0091"> <h6 class="title">Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)</h6> <p>In the study by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>, ketamine injection produced hallucinations in four participants: three experienced hallucinations whilst receiving 0.25 mg/kg and 0.5 mg/kg ketamine, and one further participant experienced hallucinations when receiving ketamine 0.5 mg/kg. All were treated with diazepam 1 mg. In addition, two participants experienced light flashes, a 'buzzing' feeling in the head, and sensation of insobriety. Diazepam resolved these symptoms. No significant changes in the Mini‐Mental State Examination (MMSE) were observed. </p> </section> <section id="CD003351-sec-0092"> <h6 class="title">Ketamine dose escalation 100 mg, 300 mg, 500 mg (subcutaneous)</h6> <p>In the study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>, there was almost twice the incidence of adverse events in the ketamine arm compared with the placebo arm on day one and throughout the study. Psychomimetic adverse events were assessed daily using the Clinician‐Administered Dissociative States Scale (CADSS). CADSS scores were not reported but 17 cognitive disturbance events with grading worse than at baseline were recorded in the ketamine group and eight such events were recorded in the placebo group. Thirteen confusion events with grading worse than baseline were recorded in the ketamine group and nine such events were recorded in the placebo group. Psychomimetic toxicity was treated with haloperidol or midazolam at specified doses. </p> </section> </section> <section id="CD003351-sec-0093"> <h5 class="title">Other adverse events</h5> <section id="CD003351-sec-0094"> <h6 class="title">Ketamine 1.0 mg twice daily (intrathecal)</h6> <p>On direct questioning, participants reported a number of adverse effects during the trial conducted by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a>: </p> <p> <ul id="CD003351-list-0008"> <li> <p>pruritis;</p> </li> <li> <p>constipation;</p> </li> <li> <p>urinary retention;</p> </li> <li> <p>difficulty in urinating;</p> </li> <li> <p>nausea and vomiting;</p> </li> <li> <p>hallucinations;</p> </li> <li> <p>respiratory depression.</p> </li> </ul> </p> <p>However, these adverse events could not be attributed specifically to the study treatments as some were present prior to the commencement of the study. </p> </section> <section id="CD003351-sec-0095"> <h6 class="title">Ketamine 0.25 mg/kg and 0.5 mg/kg (intravenous)</h6> <p>Information on the following adverse events were sought in the trial conducted by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>: </p> <p> <ul id="CD003351-list-0009"> <li> <p>drowsiness;</p> </li> <li> <p>nausea and vomiting;</p> </li> <li> <p>dry mouth.</p> </li> </ul> </p> <p>These adverse events were assessed on a scale from zero to three, where zero was 'not at all', and three was 'awful'. Participants treated with 0.25 mg/kg and 0.5 mg/kg ketamine reported increased drowsiness. </p> </section> <section id="CD003351-sec-0096"> <h6 class="title">Ketamine dose escalation 100 mg, 300 mg, 500 mg (subcutaneous)</h6> <p>In the trial by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>, adverse events were graded according to the National Institutes of Health Common Terminology Criteria for Adverse Events, version 3.0 (<a href="./references#CD003351-bbs2-0022" title="Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events V3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. ">Cancer Therapy Evaluation Program Version 3</a>). There was almost twice the incidence of adverse events in the ketamine arm compared with the placebo arm at the end of day one and throughout the study. The authors reported 31 episodes of injection site reactions, which were reported as nearly three times more likely than the placebo group. There were relatively few adverse events higher than grade three in severity (14 for ketamine; 16 for placebo). Seven serious adverse events were reported, two of which (bradyarrhythmia and cardiac arrest, both in participants receiving ketamine) were thought to be possibly related to the study drug. </p> <p>Both the trial by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and the trial by <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> reported that the adverse events of ketamine were not serious. </p> </section> </section> </section> <section id="CD003351-sec-0097"> <h4 class="title">Study withdrawals and dropouts</h4> <p>No study withdrawals or dropouts were reported in either trial by <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> or <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a>. In the study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a>, 39 participants in the ketamine group and 55 participants in the placebo group withdrew from the trial. Sixteen participants in each group discontinued the study due to clinical deterioration, patient/ clinical request or change in therapy. Nineteen participants in the ketamine group and 37 participants in the placebo group discontinued due to treatment failure. Of these, 17 in the ketamine group and two in the placebo group discontinued due to toxicity. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003351-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003351-sec-0098"></div> <section id="CD003351-sec-0099"> <h3 class="title" id="CD003351-sec-0099">Summary of main results</h3> <p>There are three included studies in the current version of the review. Two small early studies <a href="./references#CD003351-bbs2-0003" title="YangCY , WongCS , ChangJY . Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Canadian Journal of Anaesthesia1996;43(4):379‐83. ">Yang 1996</a> and <a href="./references#CD003351-bbs2-0002" title="MercadanteS , ArcuriE , TirelliW , CasuccioA . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double‐blind, crossover, double‐dose study. Journal of Pain and Symptom Management2000;4:246‐51. ">Mercadante 2000</a> report reduction in pain intensity and reduction in morphine requirements. These two studies are of high risk of bias due to small sample size, and incomplete reporting. The new study from <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> has unclear risk of bias due to size and incomplete reporting. <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> reports no difference in their primary outcomes between groups. Overall, we cannot provide a reliable indication of the likely effect of ketamine, at any dose, as an adjuvant to opioids in cancer pain. Adverse events such as hallucinations and cognitive disturbance were reported for higher doses of ketamine. Two serious adverse events (bradyarrhythmia and cardiac arrest) reported in the trial examining rapid titration of ketamine to high dose were thought to be possibly related to the study drug. </p> <p>There is large body of evidence demonstrating the efficacy of ketamine in acute postoperative pain. While this evidence cannot be directly extrapolated to other patient groups, it is important to note the complex pathophysiology of cancer pain and the difficulties of conducting clinical trials in palliative care. The authors of the study by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> should be commended for recruiting an impressive number of participants. The data from this trial could potentially provide further information on clinical questions such as whether ketamine has beneficial interactions with specific opioids, since both preclinical and clinical research have suggested that this is the case when ketamine is used as an adjuvant to morphine (<a href="./references#CD003351-bbs2-0047" title="LiliusTO , JokinenV , NeuvonenMS , NiemiM , KalsoEA , RauhalaPV . Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. British Journal of Pharmacology2015;172(11):2799‐813. ">Lilius 2015</a>). To date, the fact that the participants in the <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> trial used different opioids has not been addressed and the subgroup analyses based on type and dose of opioid have not been reported. We contacted the authors with a request for access to individual patient data, however the request was declined because such analyses were not stated in our original protocol for this review. </p> <p>It is worth noting, also, that the dose escalation in the <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> trial was very rapid, considering the pharmacokinetics of ketamine which has a short α half‐life (two to four minutes) and longer β half‐life (two to four hours) in humans (<a href="./references#CD003351-bbs2-0061" title="PeltoniemiMA , HagelbergNM , OlkkolaKT , SaariTI . Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anaesthesia and pain therapy. Clinical Pharmacokinetics2016;55(9):1059‐77. ">Peltoniemi 2016</a>), and where steady state is achieved after five elimination half‐lives. The metabolite norketamine, which is also active has a much longer half‐life than ketamine, and very ill cancer patients would be likely to have a much poorer elimination than young healthy volunteers. Ketamine doses in the <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> trial were higher than those used in the majority of ketamine regimens described in the literature. It is interesting that ketamine was found to have better effect in patients with high pain scores, however this was not mentioned in the abstract. The same finding is reported in a systematic review of 70 randomised controlled trials of intravenous ketamine for postoperative analgesia (<a href="./references#CD003351-bbs2-0044" title="LaskowskiK , StirlingA , McKayWP , LimHJ . A systematic review of intravenous ketamine for postoperative analgesia. Canadian Journal of Anesthesia2011;58:911‐23. ">Laskowski 2011</a>). In clinical practice, ketamine is usually considered to be a third‐line drug which is reserved for patients with high pain intensity scores, despite adequate ongoing opioid therapy and co‐analgesics. <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> included patients with a BPI pain intensity score of three at baseline and also patients being treated with comparatively low doses of opioid. </p> <p>All three trials used pain intensity scores as the primary outcome. Percentage pain relief may be a more useful and reliable outcome measure (<a href="./references#CD003351-bbs2-0026" title="DworkinRH , TurkDC , Wyrwich , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. ">Dworkin 2008</a>). </p> <section id="CD003351-sec-0100"> <h4 class="title">Other reports considered in the original review (2003)</h4> <p>Because of the paucity of data available from RCTs in the original review, we considered information presented in case studies and case series reports of ketamine for chronic cancer pain. In addition to the two RCTs included, the original review (2003) identified 32 case reports or open‐label, uncontrolled trials describing improvement of opioid analgesia with ketamine. We did not consider case studies and reports in the updated review. </p> <p>Whilst the design of these studies and the issue of publication of positive outcomes preclude the inclusion of any data from these reports in this systematic review, the studies were discussed in the original review and are reported in this update in order to provide a more comprehensive review of the literature on this topic. Case reports cannot provide evidence for efficacy but may provide valuable information on adverse effects. They are, by definition, all of low quality. </p> <p>The 32 reports described the use of ketamine to treat refractory cancer pain, frequently described as neuropathic pain. The total number of participants treated with ketamine in these reports was 246. The route of ketamine administration included oral, intramuscular bolus, subcutaneous bolus and infusion, intravenous bolus and infusion, epidural bolus, and intrathecal infusion. Ketamine doses ranged from 1 mg/kg/day subcutaneous infusion to 600 mg/day intravenously and 67.2 mg/day intrathecally. Treatment duration ranged from four hours to one year. Treatment was in most cases adjuvant to opioid and other drugs. Twenty‐eight reports described improved analgesia with ketamine. Where ketamine was administered as an adjuvant to opioids, the most commonly used opioid was morphine, but in some cases ketamine was given as an adjuvant to fentanyl (<a href="./references#CD003351-bbs2-0072" title="VenturaGJ , BlacklockDM . Intravenous ketamine HCL for treatment of intractable neuropathic cancer pain (INCP). Proceedings of the Annual Meeting of the American Society of Clinical Oncology1993;12:A1528. ">Ventura 1993</a>; <a href="./references#CD003351-bbs2-0017" title="BellRF . Low‐dose subcutaneous ketamine infusion and morphine tolerance. Pain1999;83:101‐3. ">Bell 1999</a>), hydromorphone (<a href="./references#CD003351-bbs2-0030" title="FinePG . Low‐dose ketamine in the management of opioid nonresponsive terminal cancer pain. Journal of Pain and Symptom Management1999;17:296‐300. ">Fine 1999</a>) or diamorphine (<a href="./references#CD003351-bbs2-0033" title="GarryAC , SimpsonKH . A difficult pain problem: Use of intrathecal ketamine. Pain Clinic1996;9(3):335‐42. ">Garry 1996</a>), or combinations of these. Ketamine was also used as sole analgesic in three reports (<a href="./references#CD003351-bbs2-0060" title="ParadaJF . Treatment of pain in cancer with ketamine hydrochloride. 13th Congreso Argentino de Anestesiologia, 1971 vol. 1; 101‐5. Buenos Aires, Oct 1971. ">Parada 1971</a>; <a href="./references#CD003351-bbs2-0073" title="Whizar‐LugoV , Cortez GomezC . Epidural ketamine vs epidural morphine in severe cancer pain. Pain1987;4 (Suppl):S142. ">Whizar‐Lugo 1987</a>; <a href="./references#CD003351-bbs2-0058" title="OshimaE , TeiK , KayazawaH , UrabeN . Continuous subcutaneous injection of ketamine for cancer pain. Canadian Journal of Anesthesia1990;37(3):385‐6. ">Oshima 1990</a>). Sixteen reports described dramatic relief of refractory cancer pain with ketamine: "complete cessation of pain" (<a href="./references#CD003351-bbs2-0072" title="VenturaGJ , BlacklockDM . Intravenous ketamine HCL for treatment of intractable neuropathic cancer pain (INCP). Proceedings of the Annual Meeting of the American Society of Clinical Oncology1993;12:A1528. ">Ventura 1993</a>); "complete relief of pain" (<a href="./references#CD003351-bbs2-0068" title="TarumiY , WatanabeS , BrueraE , IshitaniK . High dose ketamine in the management of cancer‐related neuropathic pain. Journal of Pain and Symptom Management2000;19(6):405‐7. ">Tarumi 2000</a>); "disappearance of pain" (<a href="./references#CD003351-bbs2-0060" title="ParadaJF . Treatment of pain in cancer with ketamine hydrochloride. 13th Congreso Argentino de Anestesiologia, 1971 vol. 1; 101‐5. Buenos Aires, Oct 1971. ">Parada 1971</a>; <a href="./references#CD003351-bbs2-0033" title="GarryAC , SimpsonKH . A difficult pain problem: Use of intrathecal ketamine. Pain Clinic1996;9(3):335‐42. ">Garry 1996</a>); "no pain" (<a href="./references#CD003351-bbs2-0030" title="FinePG . Low‐dose ketamine in the management of opioid nonresponsive terminal cancer pain. Journal of Pain and Symptom Management1999;17:296‐300. ">Fine 1999</a>); "pain free" (<a href="./references#CD003351-bbs2-0055" title="MitchellAC . Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliative Medicine1999;13(5):427‐8. ">Mitchell 1999</a>),; "mostly pain free" (<a href="./references#CD003351-bbs2-0048" title="Lloyd‐WilliamsM . Ketamine for cancer pain. Journal of Pain and Symptom Management2000;19(2):79‐80. ">Lloyd‐Williams 2000</a>); dramatic reduction in visual analogue scales (VAS) scores including VAS 100 reduced to zero (<a href="./references#CD003351-bbs2-0017" title="BellRF . Low‐dose subcutaneous ketamine infusion and morphine tolerance. Pain1999;83:101‐3. ">Bell 1999</a>); average VAS score 8.3 reduced to one (<a href="./references#CD003351-bbs2-0039" title="KanamaruT , SaekiS , KatsumataN , MizunoK , OgawaS , SuzukiH . Ketamine infusion for control of pain in patients with advanced cancer. Masui1990;39(10):1368‐71. ">Kanamaru 1990</a>); average VAS score reduced from 5.9 +/‐ 2.0 to 0.3 +/‐ 0.8 (<a href="./references#CD003351-bbs2-0057" title="OgawaS , KanamaruT , NodaK , SaekiS , KatsumataN , KatoJ , et al. Intravenous microdrip infusion of ketamine in subanaesthetic doses for intractable terminal cancer pain. Pain Clinic1994;7(2):125‐9. ">Ogawa 1994</a>); VAS 7/10 reduced to 1/10 (<a href="./references#CD003351-bbs2-0075" title="WoodT , SloanR . Successful use of ketamine for central pain. Palliative Medicine1997;11:57‐8. ">Wood 1997</a>); reduction of VAS 7/10 to below 2/10 (<a href="./references#CD003351-bbs2-0050" title="LossignolD , ObiolsM , BodyJJ . Ketamine and morphine in cancer pain [abstract]. 9th World Congress on Pain; Vienna, Austria. Seattle: International Association for the Study of Pain, 22 ‐ 27 August, 1999. ">Lossignol 1999</a>); "dramatic drop in VAS" (<a href="./references#CD003351-bbs2-0049" title="LossignolD , GilT , RossiC , SosnowskiM , ObiolsM , VanmeerhaegheB , et al. Cancer pain: A new concept. International Symposium on Supportive Care In Cancer; Bruges, Belgium. 8 ‐ 11 June, 1992:59. ">Lossignol 1992</a>); "remarkable analgesia" (<a href="./references#CD003351-bbs2-0032" title="FukuidaE , GochoC , ItoK . Pain in the terminal stage of cancer. IRYO Japanese Journal of National Medical Services1981;35(6):584‐7. ">Fukuida 1981</a>); "excellent analgesia" (<a href="./references#CD003351-bbs2-0065" title="SosnowskiM , LossignolD , FodderieL . Reversibility of opioid insensitive pain (abstract). World Congress on Pain. Seattle: IASP Publications, 1993:16. ">Sosnowski 1993</a>; <a href="./references#CD003351-bbs2-0054" title="MercadanteS , LodiF , SapioM , CalligaraM , SerrettaR . Long‐term ketamine subcutaneous continuous‐infusion in neuropathic cancer pain. Journal of Pain and Symptom Management1995;10(7):564‐8. ">Mercadante 1995</a>). </p> <p>The most commonly reported adverse events in this literature were sedation and hallucination. In general, adverse events were not reported as severe and only two studies reported patient withdrawal from treatment because of unacceptable "adverse cognitive effects" (<a href="./references#CD003351-bbs2-0033" title="GarryAC , SimpsonKH . A difficult pain problem: Use of intrathecal ketamine. Pain Clinic1996;9(3):335‐42. ">Garry 1996</a>), and pronounced sedation (<a href="./references#CD003351-bbs2-0042" title="KlahrM , GomasJM , LarroutureA , VinceneuxP . Treatment of neurogenic pain in adult cancer patients. A retrospective study. Presse Medicale1997;26(20):960‐3. ">Klahr 1997</a>). One report described sedation which improved on tapering the opioid dose (<a href="./references#CD003351-bbs2-0017" title="BellRF . Low‐dose subcutaneous ketamine infusion and morphine tolerance. Pain1999;83:101‐3. ">Bell 1999</a>). Other side effects described included evoked nystagmus (jerky eye movements) during treatment with intravenous ketamine (<a href="./references#CD003351-bbs2-0050" title="LossignolD , ObiolsM , BodyJJ . Ketamine and morphine in cancer pain [abstract]. 9th World Congress on Pain; Vienna, Austria. Seattle: International Association for the Study of Pain, 22 ‐ 27 August, 1999. ">Lossignol 1999</a>), and inflammation of syringe driver sites during subcutaneous treatment (<a href="./references#CD003351-bbs2-0058" title="OshimaE , TeiK , KayazawaH , UrabeN . Continuous subcutaneous injection of ketamine for cancer pain. Canadian Journal of Anesthesia1990;37(3):385‐6. ">Oshima 1990</a>; <a href="./references#CD003351-bbs2-0055" title="MitchellAC . Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliative Medicine1999;13(5):427‐8. ">Mitchell 1999</a>). One report described generalised hyperalgesia and allodynia after abrupt termination of subcutaneous ketamine infusion (<a href="./references#CD003351-bbs2-0055" title="MitchellAC . Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliative Medicine1999;13(5):427‐8. ">Mitchell 1999</a>). One postmortem report described subpial vacuolar myelopathy in a participant who had received continuous intrathecal ketamine infusion (<a href="./references#CD003351-bbs2-0040" title="KarpinskiN , DunnJ , HansenL , MasliahE . Subpial vacuolar myelopathy after intrathecal ketamine: report of a case. Pain1997;73(1):103‐5. ">Karpinski 1997</a>), while another described focal lymphocytic vasculitis close to the intrathecal catheter site (<a href="./references#CD003351-bbs2-0067" title="StotzM , OehenHP , GerberH . Histological findings after long‐term infusion of intrathecal ketamine for chronic pain: a case report. Journal of Pain and Symptom Management1999;18(3):223‐8. ">Stotz 1999</a>). One report described maintenance of syringe driver sites with topical 0.1% hydrocortisone cream (<a href="./references#CD003351-bbs2-0048" title="Lloyd‐WilliamsM . Ketamine for cancer pain. Journal of Pain and Symptom Management2000;19(2):79‐80. ">Lloyd‐Williams 2000</a>). </p> </section> </section> <section id="CD003351-sec-0101"> <h3 class="title" id="CD003351-sec-0101">Overall completeness and applicability of evidence</h3> <p>The two small studies (30 participants) included in the original review provided insufficient data to enable any evidence‐based conclusions about the benefits and harms of adjuvant ketamine to be drawn. The larger trial by <a href="./references#CD003351-bbs2-0001" title="HardyJ , QuinnS , FazekasB , PlummerJ , EckermannS , AgarM , et al. Randomized, double‐blind, placebo‐controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology2012;30(29):3611‐7. ">Hardy 2012</a> reported negative outcomes for a rapid titration, high‐dose ketamine regimen. </p> </section> <section id="CD003351-sec-0102"> <h3 class="title" id="CD003351-sec-0102">Quality of the evidence</h3> <p>The evidence from this review is limited to three very different studies which could not be combined. There are two very small studies undertaken in the 1990s of low‐dose ketamine, and one larger multi‐centre modern trial reported in 2012 on rapid titration of ketamine to high dose. Overall, the quality of the evidence base is very low and cannot provide a reliable indication of any likely effect across outcomes. </p> </section> <section id="CD003351-sec-0103"> <h3 class="title" id="CD003351-sec-0103">Potential biases in the review process</h3> <p>We are unaware of any potential biases in the review process.</p> </section> <section id="CD003351-sec-0104"> <h3 class="title" id="CD003351-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>A qualitative systematic review of ketamine for cancer pain in adults and children concluded that despite limited available data, there is evidence that ketamine may be a "viable option" for cancer pain that is poorly responsive to opioid therapy, that it appears to contribute to decreased opioid use and improved pain control (<a href="./references#CD003351-bbs2-0021" title="BredlauAL , ThakurR , CoronesDN , DworkinRH . Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Medicine2013;14(10):1505‐17. ">Bredlau 2013</a>). The authors of this review specifically wanted to perform a comprehensive review of all available data. They included the same three RCTs included in our review and in addition, two trials which were excluded by our review (<a href="./references#CD003351-bbs2-0006" title="LaurettiGR , LimaICPR , ReisMP , PradoWA , PereiraNL . Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology1999;90:1528‐33. ">Lauretti 1999a</a>; <a href="./references#CD003351-bbs2-0007" title="LaurettiGR , GomesJMA , ReisMP , PereiraNL . Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. Journal of Clinical Anaesthesia1999;11(8):663‐8. ">Lauretti 1999b</a>) (see <a href="./references#CD003351-sec-0167" title="">Characteristics of excluded studies</a>). They also included six prospective, non‐randomised, uncontrolled trials and one retrospective case series of more than 10 participants. </p> <p>A recent systematic review on adjuvant analgesics for cancer pain found that there is low‐grade evidence suggesting that ketamine as an adjuvant to opioid in cancer pain leads to pain reduction, but conclude that there is generally insufficient evidence on the effectiveness of NMDA receptor antagonists in cancer pain (<a href="./references#CD003351-bbs2-0071" title='van denBeuken‐van EverdingenMHJ , deGraeffA , JongenJLM , DijkstraD , MostovayaI , VissersC , the national guideline working group "Diagnosis treatment of cancer pain". Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review. Pain Practice2017;17(3):409‐19. '>van den Beuken‐van Everdingen 2017</a>). This review considered our Cochrane update from 2012, the review by <a href="./references#CD003351-bbs2-0021" title="BredlauAL , ThakurR , CoronesDN , DworkinRH . Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Medicine2013;14(10):1505‐17. ">Bredlau 2013</a>, and a RCT excluded from our last update (<a href="./references#CD003351-bbs2-0008" title="SalasS , FrascaM , Planchet‐BarraudB , BurucoaB , PascalM , LapianaJ‐M , et al. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. Journal of Palliative Medicine2012;15(3):287‐93. ">Salas 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003351-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/urn:x-wiley:14651858:media:CD003351:CD003351-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_t/tCD003351-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003351-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003351-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/urn:x-wiley:14651858:media:CD003351:CD003351-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_t/tCD003351-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003351-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003351-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/urn:x-wiley:14651858:media:CD003351:CD003351-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_t/tCD003351-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003351-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/full#CD003351-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003351.pub3/media/CDSR/CD003351/image_n/nCD003351-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003351.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003351-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003351-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD003351-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003351-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003351-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003351\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003351\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003351\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003351\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003351\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003351.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003351.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003351.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003351.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003351.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715587588"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003351.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715587592"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003351.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8abfd89c9371',t:'MTc0MDcxNTU4Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 